ArticleThe Lancet regional health. Western Pacific2021
The Epidemiology of COVID-19 in Malaysia.
Article in The Lancet regional health. Western Pacific, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of COVID-19 Pandemic on Healthcare Utilization among Patients with Type 2 Diabetes Mellitus: A Systematic Review.International journal of environmental research and public health · 2023Pooled it
- Not all heroes wear capes: a photovoice exploration of youth experiences during and beyond COVID-19.BMC public health · 2026Article
- Seroprevalence of SARS-CoV-2 in Livestock in Sarawak, East Malaysia.Transboundary and emerging diseases · 2026Article
- Associations of parental connectedness and monitoring with high-risk behaviors among Malaysian adolescents: a nationally representative study.BMC public health · 2025Article
- Article
- Article
- Trends in cataract surgery and healthcare system response during the COVID-19 lockdown in Malaysia: Lessons to be learned.Public health in practice (Oxford, England) · 2024Article
- Implementation pilot study of community self-testing for COVID-19 among employees of manufacturing industries and their household members in 2022 to 2023.PLOS global public health · 2024Article
- Utilisation of the web-based Home Assessment Tool among patients with COVID-19 in Selangor, Malaysia: An observational study.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2024Article
- Assessing the impact of COVID-19 on epidemiological changes of severe pediatric respiratory syncytial virus infections in Malaysia.Frontiers in public health · 2024Article
- Understanding the progress of COVID-19 transmission in a rural district: a social network approach.PeerJ · 2024Article
- Exploration of spatiotemporal heterogeneity and socio-demographic determinants on COVID-19 incidence rates in Sarawak, Malaysia.BMC public health · 2023Article
- Establishing a hyperacute stroke service during the COVID-19 pandemic: our institution's one year experience.BMC neurology · 2023Article
- Risk analysis of musculoskeletal pain intervention using corticosteroid during COVID-19 pandemic: a cohort study.The Korean journal of pain · 2023Article
- Using Andersen's model of health care utilization to assess factors associated with COVID-19 testing among adults in nine low-and middle-income countries: an online survey.BMC health services research · 2022Article
- COVID-19 Inpatient Deaths and Brought-in-Dead Cases in Malaysia.Frontiers in public health · 2022Article
- Adaptation and Validation of the Malay Version of the Stress and Anxiety to Viral Epidemics-6 Items Scale Among the General Population.Frontiers in psychiatry · 2022Article
- Assessing the Spatiotemporal Spread Pattern of the COVID-19 Pandemic in Malaysia.Frontiers in public health · 2022Article
- COVID-19: What we need from epidemiology to help informed policies.The Lancet regional health. Western Pacific · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 has rapidly spread across the globe. Critical to the control of COVID-19 is the characterisation of its epidemiology. Despite this, there has been a paucity of evidence from many parts of the world, including Malaysia. We aim to describe the epidemiology of COVID-19 in Malaysia to inform prevention and control policies better.
methodsMalaysian COVID-19 data was extracted from 16 March 2020 up to 31 May 2021. We estimated the following epidemiological indicators: 7-day incidence rates, 7-day mortality rates, case fatality rates, test positive ratios, testing rates and the time-varying reproduction number (Rt).
findingsBetween 16 March 2020 and 31 May 2021, Malaysia has reported 571,901 cases and 2,796 deaths. Malaysia's average 7-day incidence rate was 26•6 reported infections per 100,000 population (95% CI: 17•8, 38•1). The average test positive ratio and testing rate were 4•3% (95% CI: 1•6, 10•2) and 0•8 tests per 1,000 population (95% CI: <0•1, 3•7), respectively. The case fatality rates (CFR) was 0•6% (95% CI: <0•1, 3•7). Among the 2,796 cases who died, 87•3% were ≥ 50 years.
interpretationThe public health response was successful in the suppression of COVID-19 transmission or the first half of 2020. However, a state election and outbreaks in institutionalised populations have been the catalyst for more significant community propagation. This rising community transmission has continued in 2021, leading to increased incidence and strained healthcare systems. Calibrating NPI based on epidemiological indicators remain critical for us to live with the virus. (243 words).
fundingThis study is part of the COVID-19 Epidemiological Analysis and Strategies (CEASe) Project with funding from the Ministry of Science, Technology and Innovation (UM.0000245/HGA.GV).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.